WAVERLEY PHARMA INC.

Research WAVERLEY PHARMA INC. (5GZ) on Bullrun: market cap EUR 496.64K. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker5GZ
ExchangeF
CountryCanada
SectorHealthcare
IndustryBiotechnology
CurrencyEUR
Market capEUR 496.64K
Financial periodQ1 2026
RevenueCAD 287.13K
Net income-CAD 165.47K
Free cash flow-CAD 65.14K
Gross margin32.6%

Valuation Snapshot

latest market cap is EUR 496.64K.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CAD 2.90M	-CAD 627.05K	-CAD 611.03K	40.2%	n/a	CAD 44.95K	CAD 3.44M	-CAD 2.57M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-27	EUR 496.64K	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About WAVERLEY PHARMA INC.

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

Related stock research

Canada stocks Canada Healthcare stocks A-Z stock index

Other Healthcare stocks

Entheon Biomedical Corp. (1XU) NANOSPHERE HEA.SCIENCES (2CG) MedMira Inc (47M) BRAXIA SCIENTIFIC CORP. (4960) BioVaxys Technology Corp. (5LB0) GLOW LIFETECH CORP. (9DO) NERVGEN PHARMA CORP. (9UA) AbCellera Biologics Inc (ABCL) Appili Therapeutics Inc (APLI) Arch Biopartners Inc (ARCH) Aurinia Pharmaceuticals Inc (AUPH) Briacell Therapeutics Corp (BCT)

Frequently asked questions

What is WAVERLEY PHARMA INC.'s market cap?

WAVERLEY PHARMA INC.'s market capitalization is EUR 496.64K.